Market revenue in 2023 | USD 2,560.0 million |
Market revenue in 2030 | USD 3,941.0 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Molecular diagnostics |
Fastest growing segment | Immunoassays |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoassays, Hematology and Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy |
Key market players worldwide | Quest Diagnostics Inc, 23andMe Holding Co Class A, Abbott Laboratories, Guardant Health Inc, NeoGenomics, Siemens Healthineers AG ADR, Qiagen NV, Illumina Inc, Roche Holding AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to laboratory developed tests market will help companies and investors design strategic landscapes.
Molecular diagnostics was the largest segment with a revenue share of 24.21% in 2023. Horizon Databook has segmented the Asia Pacific laboratory developed tests market based on immunoassays, hematology and coagulation, molecular diagnostics, microbiology, clinical chemistry, histology/cytology, flow cytometry, mass spectroscopy covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of key market players in the region, such as Sysmex Corporation, is expected to boost the market. Sysmex Corporation is undertaking initiatives to promote personalized therapeutics in primary care testing closer to patients.
It is developing companion diagnostic drugs and testing technologies for analyzing proteins, genes, disease-derived cells, & other elements in the blood or other body fluids. For instance, in May 2022, Sysmex Inostics announced plans to expand its blood test offering for Acute Myeloid Leukemia (AML) detection.
In addition, significant R&D is underway in RIKEN, a key research institute in Japan, for the analysis and development of novel biomarkers. Major research agencies in Canada and Japan have collaborated to gain an understanding of the mechanism of genetic mutations.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific laboratory developed tests market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific laboratory developed tests market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account